Loading company…
Quotient Therapeutics studies cellular genetic variation to discover potential disease treatments.
Founded in 2021 and based in London, Quotient Therapeutics is developing a somatic genome platform to find genetic variations linked to disease. Its research may support treatments for immune, cardiometabolic, infectious, cancer, neurological, rare, and age-related conditions. It was co-founded by Jake Rubens and is led by CEO Geoffrey Maltzahn. In November 2023, it raised USD 50 million in Series A funding led by Flagship Pioneering.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in